📊 NUTX Key Takeaways
Is Nutex Health Inc. (NUTX) a Good Investment?
Nutex Health demonstrates exceptional fundamental strength with 82.4% revenue growth and robust profitability margins (50.8% gross, 31.5% operating). The company generates substantial free cash flow of $245.6M (28.1% FCF margin) while maintaining fortress-like balance sheet strength with minimal leverage (0.09x debt/equity) and exceptional liquidity (3.41x current ratio).
Nutex Health shows exceptional revenue growth with strong gross and operating margins, translating into robust free cash flow and supported by a highly liquid, low-leverage balance sheet. Despite flat net income YoY, operating performance and cash generation indicate healthy core fundamentals; sustaining growth without margin or reimbursement pressure is the key.
Why Buy Nutex Health Inc. Stock? NUTX Key Strengths
- Exceptional revenue growth of 82.4% YoY demonstrates strong market demand and successful execution
- Outstanding profitability metrics with 50.8% gross margin and 31.5% operating margin indicating pricing power and operational efficiency
- Fortress balance sheet with $185.6M cash, minimal debt ($29.2M), and 0.09x debt/equity ratio providing financial flexibility
- Exceptional free cash flow generation of $245.6M (28.1% FCF margin) with minimal capex needs ($2.5M)
- Strong returns on equity (21.5%) and assets (7.7%) demonstrating efficient capital deployment
- Exceptional liquidity with 3.41x current ratio and 3.39x quick ratio indicating strong working capital position
- Rapid revenue growth with strong operating leverage
- High cash conversion and FCF margin (~28%)
- Excellent liquidity, minimal debt, and high interest coverage
NUTX Stock Risks: Nutex Health Inc. Investment Risks
- Revenue growth of 82.4% may not be sustainable long-term; company must demonstrate consistency
- Net margin of 8.1% significantly lags operating margin of 31.5%, indicating substantial below-operating-line expenses or tax burden requiring investigation
- Net income was flat YoY despite 82.4% revenue growth, suggesting margin compression or non-operating headwinds need clarification
- 16 Form 4 filings in 90 days warrants monitoring for insider sentiment changes or potential governance concerns
- Business services sector (SIC 7389) remains competitive; sustaining high margins requires continued differentiation
- Sustainability of 80%+ revenue growth and potential reliance on expansion or acquisitions
- Flat net income despite revenue surge suggests nonrecurring items or below-the-line pressures
- Healthcare reimbursement and payer-mix/regulatory changes could compress margins and cash flow
Key Metrics to Watch
- Revenue growth sustainability in upcoming quarters; watch for deceleration signals
- Net margin expansion drivers; investigate gap between 31.5% operating margin and 8.1% net margin
- Free cash flow conversion and capital efficiency as company scales
- Gross margin stability; ensure 50.8% gross margin is defensible
- Insider transaction patterns; monitor for any negative sentiment shifts
- Operating margin
- Cash conversion (OCF / Net Income)
Nutex Health Inc. (NUTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 28.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.41x current ratio provides a solid financial cushion.
NUTX Profit Margin, ROE & Profitability Analysis
NUTX vs Services Sector: How Nutex Health Inc. Compares
How Nutex Health Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nutex Health Inc. Stock Overvalued? NUTX Valuation Analysis 2026
Based on fundamental analysis, Nutex Health Inc. appears fundamentally strong relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nutex Health Inc. Balance Sheet: NUTX Debt, Cash & Liquidity
NUTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nutex Health Inc.'s revenue has grown significantly by 4,557% over the 5-year period, indicating strong business expansion. The most recent EPS of $-10.39 indicates the company is currently unprofitable.
NUTX Revenue Growth, EPS Growth & YoY Performance
NUTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $78.8M | -$8.8M | $-1.72 |
| Q2 2025 | $76.1M | -$364.0K | $-0.07 |
| Q1 2025 | $67.5M | -$364.0K | $-0.08 |
| Q3 2024 | $62.7M | -$5.5M | $-1.25 |
| Q2 2024 | $58.9M | -$364.0K | $-0.07 |
| Q1 2024 | $56.3M | -$364.1K | $-0.01 |
| Q3 2023 | $28.4M | -$5.5M | $-0.01 |
| Q2 2023 | $58.0M | $2.2M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nutex Health Inc. Dividends, Buybacks & Capital Allocation
NUTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nutex Health Inc. (CIK: 0001479681)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUTX
What is the AI rating for NUTX?
Nutex Health Inc. (NUTX) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUTX's key strengths?
Claude: Exceptional revenue growth of 82.4% YoY demonstrates strong market demand and successful execution. Outstanding profitability metrics with 50.8% gross margin and 31.5% operating margin indicating pricing power and operational efficiency. ChatGPT: Rapid revenue growth with strong operating leverage. High cash conversion and FCF margin (~28%).
What are the risks of investing in NUTX?
Claude: Revenue growth of 82.4% may not be sustainable long-term; company must demonstrate consistency. Net margin of 8.1% significantly lags operating margin of 31.5%, indicating substantial below-operating-line expenses or tax burden requiring investigation. ChatGPT: Sustainability of 80%+ revenue growth and potential reliance on expansion or acquisitions. Flat net income despite revenue surge suggests nonrecurring items or below-the-line pressures.
What is NUTX's revenue and growth?
Nutex Health Inc. reported revenue of $875.3M.
Does NUTX pay dividends?
Nutex Health Inc. does not currently pay dividends.
Where can I find NUTX SEC filings?
Official SEC filings for Nutex Health Inc. (CIK: 0001479681) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUTX's EPS?
Nutex Health Inc. has a diluted EPS of $10.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nutex Health Inc. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is NUTX stock overvalued or undervalued?
Valuation metrics for NUTX: ROE of 21.5% (sector avg: 16%), net margin of 8.1% (sector avg: 10%). Higher ROE suggests strong returns relative to peers.
Should I buy NUTX stock in 2026?
Our dual AI analysis gives Nutex Health Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUTX's free cash flow?
Nutex Health Inc.'s operating cash flow is $248.1M, with capital expenditures of $2.5M. FCF margin is 28.1%.
How does NUTX compare to other Services stocks?
Vs Services sector averages: Net margin 8.1% (avg: 10%), ROE 21.5% (avg: 16%), current ratio 3.41 (avg: 1.5).